BAL In Oil Disease Interactions

The use of dimercaprol is contraindicated in patients with impaired hepatic function, except for arsenic- associated jaundice. Dimercaprol, not complexed to heavy metals, is metabolized by the liver to inactive forms in patients with normal hepatic function. Hepatic impairment decreases the metabolism of dimercaprol and can result in elimination of potentially nephrotoxic dimercaprol as well as increased CNS toxicity and hypertension.

Switch to professional interaction data

Dimercaprol is primarily eliminated by the kidney complexed with a heavy metal (lead, arsenic, mercury, gold). Dimercaprol and heavy metals are nephrotoxic and dissociate at an acid pH. Urinary alkalinization during dimercaprol therapy is necessary. The serum concentration of dimercaprol is elevated in patients with oliguria and CNS toxicity and hypertension are possible. Dimercaprol should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy. Therapy with dimercaprol should be administered very cautiously and dosages reduced in patients with oliguria. Close clinical monitoring of urine pH and renal function is necessary.

Switch to professional interaction data

Dimercaprol ampules are formulated with peanut oil. Peanut oil may cause allergic reactions in some individuals. Physicians should use caution in prescribing dimercaprol ampules for peanut-sensitive patients. Medication and equipment necessary to treat allergic reactions should be available if the product is administered to peanut-allergic patients.

Switch to professional interaction data

Dimercaprol-associated hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase deficiency. Therapy with dimercaprol should be administered with caution in patients with G6PD deficiency. Clinical monitoring of erythropoietic function including hemolysis is recommended.

Switch to professional interaction data

Dose-related increase in systolic and diastolic blood pressure, with or without accompanying tachycardia, is the most frequently reported adverse effect of dimercaprol therapy. Blood pressure may rise 15 to 30 minutes following injection and usually returns to normal within 2 hours. Therapy with dimercaprol should be administered cautiously in patients with hypertension. Clinical monitoring of blood pressure is recommended.

Switch to professional interaction data